|
Orthologous residues
|
|
CREB (human): S133‑p, CREB iso2 (human): S119‑p, CREB (mouse): S133‑p, CREB (rat): S133‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
SK-N-MC (neural crest)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
MAPKAPK2 (human)
|
pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
forskolin
|
|
|
|
increase
|
|
|
aFGF
|
|
|
|
increase
|
|
|
SB203580
|
aFGF
|
|
|
inhibit treatment-induced increase
|
|
|
forskolin
|
aFGF
|
|
|
augment treatment-induced increase
|
|
|
arsenite
|
|
|
|
increase
|
|
|
SB203580
|
arsenite
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
transcription, altered
|